论文部分内容阅读
目的 :观察拉米夫定 (3- TC)与干扰素 (IFN)联合与单用治疗慢性乙型病毒性肝炎 (CHB)的疗效。方法 :以 2种药物分别单用或联合应用 ,治疗 130例 CHB患者 ,观察治疗前后各自临床症状、AL T、病毒标志物水平的变化。结果 :治疗结束时联合用药组 HBV- DNA阴转率为 81.6 % (6 2 / 76 ) ,HBe Ag阴转率为 38.2 % (2 6 / 6 8) ,抗 - HBe阳转率为 2 5 % (17/ 6 8) ;单用 3TC组 HBV- DNA阴转率为 70 .8% (17/ 2 4) ,HBe Ag阴转率为 10 % (2 / 10 ) ,抗 - HBe阳转率为 5 % (1/ 2 0 ) ;单用 IFN组 HBV- DNA阴转率为 33.3% (10 / 30 ) ,HBe Ag阴转率为 40 % (12 / 30 ) ,抗 - HBe阳转率为 10 % (3/ 30 )。各组患者 AL T水平于 12周以后均正常。肝炎临床症状改善 ,应用 IFN者副作用稍多 ,但多数患者可以耐受治疗。结论 :联合用药组综合疗效优于单独用药组
Objective: To observe the curative effect of lamivudine (3-TC) combined with interferon (IFN) in the treatment of chronic hepatitis B (CHB). Methods: 130 patients with CHB were treated with 2 drugs alone or in combination. The changes of clinical symptoms, ALT and viral markers before and after treatment were observed. Results: At the end of treatment, the negative conversion rate of HBV DNA was 81.6% (6 2/76), the negative conversion rate of HBe Ag was 38.2% (26/68), the positive conversion rate of anti - HBe was 25% (17/24) in the 3TC group, 70.8% (17/2 4) in the 3TC group, 10% (2/10) in the HBe Ag group, and The negative conversion rate of HBeAg was 33.3% (10/30) in IFN alone group, negative conversion rate of HBe Ag was 40% (12/30) % (3/30). ALT levels in all groups were normal after 12 weeks. Hepatitis clinical symptoms improved, application of IFN side effects slightly more, but most patients can tolerate treatment. Conclusion: The combined treatment group is superior to the single treatment group